Catawba Research, striving to be a leading Contract Research Organization, announced the expansion of its Scientific Advisory Board with the addition of Mary Spellman, M.D., and Cornelis (Cees) Wortel, Ph.D.
Spellman, an experienced dermatologist, has collaborated with the FDA in developing clinical endpoints for novel indications and serves as an editorial board member for the Journal of the American Academy of Dermatology. Her knowledge of dermatology enhances Catawba Research’s support model.
Wortel, a veteran clinical leader and founder of Clinquest, brings expertise in immunology and autoimmune diseases. His background strengthens Catawba Research’s capabilities in these crucial fields.
These appointments enhance Catawba Research’s ability to assist clients in navigating clinical trial complexities. Jack McLane, Chief Scientific Officer and chair of the board emphasized the value of Spellman and Wortel’s contributions in driving innovation and supporting the development of novel therapies.
The expanded advisory board further positions Catawba Research as a leading CRO with deep knowledge in dermatology and immunology. This expertise supports sponsors in achieving successful outcomes in challenging indications.
With a team of renowned advisors, Catawba Research provides comprehensive clinical development and regulatory strategy support across various therapeutic areas and geographical regions. The expanded board reinforces Catawba Research’s commitment to achieving extraordinary results in clinical trials.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
